Production & Sales

Dr. Reddy’s to sell API manufacturing business unit in Hyderabad, India

Dr. Reddy’s Laboratories has agreed to divest its its API manufacturing business unit located in Jeedimetla, Hyderabad, located in the Indian state of Telangana, to generics pharmaceutical firm Therapiva Private.

eTheRNA immunotherapies opens mRNA manufacturing facility in Belgium

Clinical-stage firm eTheRNA immunotherapies has opened a mRNA facility in Belgium for production of mRNA immunotherapies.

Alliance Pharma launches nausea drug Xonvea in UK

Alliance Pharma has launched Xonvea, a new prescription drug for the treatment of nausea and vomiting of pregnancy (NVP), in the UK.

Dr. Reddy’s Laboratories sells antibiotic manufacturing site in Bristol, Tennessee

Dr. Reddy’s Laboratories has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a wholly owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.

Recipharm acquires Sanofi inhalation contract manufacturing business

Recipharm has completed the purchase of Sanofi’s inhalation contract manufacturing business including a manufacturing plant situated in Holmes Chapel, UK.

Dova, Salix sign exclusive co-promotion deal for Doptelet

Dova Pharmaceuticals, Salix Pharmaceuticals and its parent company Bausch Health Companies have entered into an exclusive agreement to co-promote Dova’s Doptelet (avatrombopag) in the US.

Gilead to launch generic versions of hepatitis C drugs in US

Gilead Sciences is planning to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) in the US.

Tris Pharma acquires Pfizer’s subsidiary NextWave Pharmaceuticals

Tris Pharma, a developer of technology-based therapeutic products, has acquired Pfizer’s subsidiary NextWave Pharmaceuticals for an undisclosed sum.

Symbiosis gets FDA approval for manufacturing fill/finish process

Sterile manufacturing CDMO Symbiosis Pharmaceutical Services has secured approval from the US Food and Drug Administration (FDA) for its viral vector manufacturing fill/finish process at its biologics manufacturing facility in Scotland, UK.